AMSBIO expands its range of laminin isoforms
Expanded range of laminin isoforms provides greater flexibility when tailoring your substrate to specific cells
25 Aug 2022
Designed to efficiently induce differentiation in ES and iPS cells, AMSBIO has expanded its iMatrix series of recombinant laminin E8 fragments to now include isoforms LN-111 and LN-332.
This expanded range of laminin isoforms (LN-111, 332, 511, 411, and 221) now provides even greater flexibility and control when tailoring your substrate to the requirements of specific cultured cells.
Proven in many leading life science research labs - iMatrix is used as a substrate for culturing and maintaining cells, including Pluripotent Stem Cells and Mesenchymal Stem Cells, as well as for differentiation into ectoderm, endoderm, and mesoderm. All iMatrix products offer the dual advantage of recombinant protein expression. As E8 fragments they contain all of the integrin-binding sites of full-length laminin in a much shorter protein.
New to the product range, iMatrix-111 is the E8 fragment of the LN-111 isoform, which plays significant roles in vivo and is important in cell culture. As well as being the major substrate for nerve axon growth, both in vivo and in vitro, LN-111 is also the main component of the industry standard substrates used in cell culture: Matrigel® and Cultrex® BME. iMatrix-111 has been validated to promote the differentiation of iPSCs into hepatocyte-like cells.
The Laminin-332 isoform is essential for epithelial cell adhesion to the basement membrane and iMatrix Laminin-322 has been used to induce differentiation of iPS cells into corneal epithelial cells in vitro.
